Crossmark

Efficacy of modified dendritic cell–cytokine-induced killer cells loaded with tumour stem cell membrane microparticle therapy in the treatment of relapsed or refractory T- and NK-cell lymphoid proliferations and lymphomas: a report of three cases

Crossref DOI link: https://doi.org/10.1007/s00277-026-06965-7

Published Online: 2026-04-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Ao

Fan, Tao

Zhang, Ju

Ye, Mei

Huang, Hong

Gao, Ze-Li
Funding

Funding for this research was provided by:

Panzhihua City Medical Research Center Project (PYYZ-2022–13)
License Information

Text and Data Mining valid from 2026-04-01

Version of Record valid from 2026-04-01
More Information

Article History

Received: 24 December 2025

Accepted: 16 March 2026

First Online: 1 April 2026

Declarations

:

: This study was approved by the he Affiliated Hospital of Panzhihua University Ethics Committee/Institutional Review Board (ID: 2023-03-001). Informed consent for participation in the study was obtained directly from all participating adults. For paediatric participants, informed consent was provided by their legal guardians or next of kin. Similarly, informed consent for the publication of the research data and any accompanying images was signed by the adult participants themselves, or by the legal guardians or next of kin of the paediatric participants. Both consents (for participation and for publication) are explicitly differentiated here, even if they were recorded using a single form. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below